Chronic lithium administration enhances noradrenergic responses to intravenous administration of the alpha2 antagonist idazoxan in healthy volunteers.
The acute and chronic effects of lithium carbonate administration at therapeutic blood levels on peripheral noradrenergic activity and sympathetic responses to alpha2 adrenoceptor blockade were examined in 10 medically and psychiatrically healthy volunteers. Supine resting levels of plasma norepinephrine and the increases in norepinephrine following intravenous infusion of 200 microg/kg of idazoxan, a selective alpha2 adrenoceptor antagonist, were determined before lithium (Li+) administration and after 5 days and after 4 weeks of daily Li+ treatment. Chronic Li+ treatment significantly increased mean resting plasma norepinephrine levels by 53.6%. The noradrenergic responses to infusions of idazoxan were slightly enhanced after 5 days of Li+ administration and significantly increased following 4 weeks of Li+ treatment. The possibility that Li+ produces functional alpha2 subsensitivity causing enhanced peripheral noradrenergic activity in humans is supported by the findings of increased mean resting plasma norepinephrine and increased response to idazoxan following chronic Li+ administration. Alteration of regulatory mechanisms in the noradrenergic system may be relevant to understanding the clinical effects of Li+ in manic-depressive illness.
Ozerdem
Ayşegül
A
Psychiatry Department, Dokuz Eylül University Medical School, Izmir, Turkey. aysegul.ozerdem@deu.edu.tr
Schmidt
Mark E
ME
Manji
Husseini K
HK
Risinger
Robert C
RC
Potter
William Z
WZ
D058669:Adrenergic alpha-2 Receptor Antagonists; D000317:Adrenergic alpha-Antagonists / Q000008:administration & dosage / Q000494:pharmacology*; D000328:Adult; D000368:Aged; D018692:Antimanic Agents / Q000494:pharmacology*; D002851:Chromatography, High Pressure Liquid; D005260:Female; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D019329:Idazoxan / Q000008:administration & dosage / Q000494:pharmacology*; D007275:Injections, Intravenous; D016651:Lithium Carbonate / Q000494:pharmacology*; D008297:Male; D008875:Middle Aged; D009638:Norepinephrine / Q000097:blood*; D012044:Regression Analysis; D012727:Sex Characteristics
D058669:Adrenergic alpha-2 Receptor Antagonists; D000317:Adrenergic alpha-Antagonists; D018692:Antimanic Agents; D016651:Lithium Carbonate; D009638:Norepinephrine; D019329:Idazoxan